Related Experiment Videos
Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a)
W Terres1, E Tatsis, B Pfalzer
1Department of Cardiology, University Hospital Eppendorf, Hamburg, Germany.
Insights
Elevated lipoprotein(a) [Lp(a)] is a significant risk factor for rapid coronary artery disease progression. This finding suggests Lp(a) may impede clot breakdown, contributing to faster disease advancement.
Area of Science:
- Cardiology
- Vascular Biology
- Biochemistry
Background:
- Mechanisms of rapid coronary artery disease (CAD) progression remain unclear.
- Intravascular thrombosis and plaque rupture are potential contributors.
- Understanding risk factors is crucial for managing CAD.
Purpose of the Study:
- To investigate potential risk factors for rapid angiographic progression of CAD.
- To identify specific biomarkers associated with accelerated disease development.
Main Methods:
- Prospective study of 79 patients with established CAD and significant stenosis.
- Quantitative coronary angiography performed at baseline and after a mean interval of 66 days.
- Comparison of patient demographics, traditional risk factors, and serum lipoprotein(a) [Lp(a)] levels between groups with and without rapid progression.
Main Results:
- Rapid CAD progression, defined by increased stenosis, new lesions, or vessel occlusion, occurred in 27% of patients.
- No significant differences observed in sex, age, smoking, hypertension, diabetes, LDL, HDL, or apolipoprotein B.
- Significantly higher serum Lp(a) concentrations (>= 25 mg/dL) were found in patients with rapid progression (67%) compared to those without (33%) (P = .007).
- Median Lp(a) levels were 66 mg/dL in the rapid progression group versus 13 mg/dL in the non-progression group (P = .01).
Conclusions:
- Lipoprotein(a) [Lp(a)] is identified as a risk factor for rapid angiographic progression of coronary artery disease.
- The proposed mechanism involves Lp(a) interfering with thrombolysis due to its structural similarity to plasminogen.
- This highlights Lp(a) as a potential therapeutic target for slowing CAD advancement.
Background:
The mechanisms underlying rapid angiographic progression of coronary artery disease are still unknown. Intravascular thrombosis with or without plaque rupture may be involved.
Methods And Results:
In a prospective study in 79 patients with coronary artery disease and at least one coronary diameter stenosis > or = 50%, possible risk factors for rapid progression were investigated. Quantitative coronary angiography was performed twice at a mean time interval of 66 +/- 25 days. Rapid progression of coronary disease defined as (1) an increase > 10% in stenosis severity in at least one stenosis > or = 50%, (2) occurrence of a new stenosis > or = 50%, or (3) occlusion of a formerly patent vessel was found in 21 patients (27%). Between patients with rapid progression and those without, there were no significant differences in sex distribution, age, smoking history, frequency of hypertension or diabetes mellitus, and serum LDL cholesterol, HDL cholesterol, and apolipoprotein B concentrations. In contrast, serum lipoprotein(a) [Lp(a)] concentrations > or = 25 mg/dL were found in 14 of 21 patients (67%) with rapid progression of coronary artery disease but in only 19 of 58 (33%) in the group without progression (P = .007). The respective median Lp(a) concentrations were 66 mg/dL (range, 2 to 139) and 13 mg/dL (range, 2 to 211; P = .01).
Conclusions:
Lp(a) appears to be a risk factor for the rapid angiographic progression of coronary artery disease. The pathophysiological link between Lp(a) and rapid progression may be an interference with thrombolysis through the partial structural homology of Lp(a) with plasminogen.